NEW YORK (GenomeWeb) - NeoGenomics today reported that its third quarter revenues increased 8 percent, just shy of Wall Street's consensus estimate. The firm also announced a change to its testing services agreement with Covance.

For the three months ended Sept. 30, revenues for the Fort Myers, Florida cancer genetic testing firm increased to $25.1 million from $23.2 million in the prior-year period. On average, analysts had expected $25.6 million in revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.